Slingshot Insights | Bmy Overview

BMY Overview

Upcoming Projects (BMY)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (BMY)

Quarterly Survey: LR-MDS Pts RBC Transfusions and Reblozyl (luspatercept) - October 2023
Tickers: BMY, MRK, GERN, ELRN
Executed On: Nov 02, 2023 at 05:25 PM EDT
Quarterly Survey: Plaque Psoriasis and Acne Laser Treatment Usage and Trends October 2023
Tickers: ARQT, BMY, CUTR, HOLX, DRMT
Executed On: Oct 30, 2023 at 05:21 PM EDT
Discussing Novel Therapies in Dermatology with a focus on TYK2 in Psoriasis, IL-13 & OX-40(L) in Atopic Dermatitis and IL-17 in Hidradenitis Suppurativa
Tickers: REGN, BMY, AMGN
Executed On: Oct 18, 2023 at 12:30 PM EDT
Quarterly Survey: LR-MDS Pts RBC Transfusions and Reblozyl (luspatercept) - July 2023
Tickers: BMY, MRK, GERN, ELRN
Executed On: Aug 01, 2023 at 03:55 PM EDT
Quarterly Survey: Plaque Psoriasis and Acne Laser Treatments - July 2023
Tickers: ARQT, BMY, CUTR, HOLX, DRMT
Executed On: Jul 31, 2023 at 04:22 PM EDT
Discussing various agents targeting BCMA and GPRC5D in multiple myeloma
Tickers: JNJ, LEGN, BMY
Executed On: Jul 12, 2023 at 06:00 PM EDT
A Second Opinion: Discussing Bristol Myers' COMMANDS (Reblozyl) & Geron's iMERGE (imetelstat) data from ASCO 2023 in MDS
Tickers: BMY, GERN
Executed On: Jun 26, 2023 at 01:00 PM EDT
Discussing Bristol Myers' COMMANDS (Reblozyl) & Geron's iMERGE (imetelstat) data from ASCO 2023 in MDS
Tickers: BMY, GERN
Executed On: Jun 07, 2023 at 02:00 PM EDT
Digging into the TRANSCEND studies for Bristol Myers' Breyanzi (lisocabtagene maraleucel) in follicular and mantle cell lymphoma
Ticker: BMY
Executed On: May 18, 2023 at 09:30 AM EDT
Quarterly Survey: BMY's Reblozyl (luspatercept) and LR-MDS requiring Red Blood Cell Transfusions May 2023
Tickers: BMY, XLRN, MRK, GERN
Executed On: May 10, 2023 at 12:29 PM EDT
Quarterly Survey: Plaque Psoriasis and Acne Laser Treatments April 2023
Tickers: BMY, ARQT, CUTR, HOLX, BHC
Executed On: Apr 11, 2023 at 04:48 PM EDT
Quarterly Survey: Plaque Psoriasis and Acne Laser Treatments February 2023
Tickers: ARQT, BMY, CUTR, HOLX, BHC
Executed On: Mar 14, 2023 at 03:16 PM EDT
An overview of next generation "oral biologics" in treating inflammatory/rheumatological disease
Tickers: IBB, ACRS, DICE, VTYX, IMUX, KYMR, BMY, PTGX, PFE
Executed On: Dec 08, 2022 at 04:00 PM EST
Digging into the Phase 1 data for REGN's LAG3 + Libtayo combination in frontline Melanoma
Tickers: REGN, BMY
Executed On: Oct 21, 2022 at 02:00 PM EDT
Digging into S1P1 modulators as treatment for Ulcerative Colitis with a focus on Zeposia (Ozanimod), Etrasimod, CBP-307 & VTX002
Tickers: BMY, PFE, CNTB, VTYX
Executed On: Sep 23, 2022 at 02:00 PM EDT
A look at the use of ELIQUIS, Xarelto, and other blood thinners for cardiovascular disease and atrial fibrillation
Tickers: BMY, JNJ
Executed On: Aug 25, 2022 at 02:00 PM EDT
A Second Look at the efficacy of Mavacamten as a treatment of hypertrophic cardiomyopathy
Tickers: BMY, LIAN
Executed On: Jun 30, 2022 at 09:00 AM EDT
A Look at the efficacy of Mavacamten as a treatment of hypertrophic cardiomyopathy
Tickers: BMY, LIAN
Executed On: Jun 29, 2022 at 02:00 PM EDT
Discussion of current NHL CAR-T and outlook for allogeneic therapies in DLBCL
Tickers: BMY, GILD, NVS, CRSP, ALLO, ACET
Executed On: May 03, 2022 at 01:00 PM EDT
A look into the current and developing S1P1 modulators as treatment for Ulcerative Colitis
Tickers: PFE, BMY, CNTB, VTYX
Executed On: Apr 22, 2022 at 01:00 PM EDT
A look at the potential of S1P modulators in moderate-severe ulcerative colitis and how they might fit into the treatment paradigm
Tickers: ARNA, BMY, CNTB
Executed On: Mar 07, 2022 at 12:00 PM EST
Discussing BCMA targeted therapies in r/r multiple myeloma
Tickers: JNJ, GSK, BMY, TSVT, LEGN
Executed On: Jan 06, 2022 at 03:00 PM EST

Expired Projects (BMY)

Discussing the clinical landscape of multiple myeloma with a focus on BCMA CAR-T
Tickers: LEGN, JNJ, TSVT, BMY
Execute By: Oct 31, 2023
Discussing recent advancements in dermatology, with a focus on AD and psoriasis
Tickers: LEGN, BMY, JNJ
Execute By: Oct 27, 2023
Discussing various modalities for BCMA targeted therapy in multiple myeloma
Tickers: JNJ, LEGN, BMY
Execute By: Oct 27, 2023
Analyzing Legend Biotech’s ciltacabtagene autoleucel, BCMA-directed chimeric antigen receptor T cell (CAR-T) therapy for the treatment of multiple myeloma, ahead of extended PDUFA February 28, 2022
Tickers: LEGN, JNJ, BMY
Execute By: Feb 28, 2022
Discussing TGTX's Umbralisib UNITY-NHL Trial In wake of Rolling NDA Submission in Marginal Zone Lymphoma/Follicular Lymphoma
Tickers: TGTX, BMY, BAYN.XFRA
Execute By: Apr 03, 2020
Discussion of IDO inhibitors from a basic science and research perspective. Specifically discussing potential bioavailability and solubility issues.
Tickers: NLNK, BMY, RHHBY
Execute By: Apr 21, 2017
Assessing the Potential of AstraZeneca's (AZN) Durvalumab + TapImmune's (TPIV) TPIV 200 in Platinum-Resistant Ovarian Cancer Ahead of Phase II Initiation This Quarter
Tickers: AZN, MRK, BMY, TPIV, RHHBY
Execute By: May 17, 2016

Upcoming & Overdue Catalysts (BMY)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (BMY)

Nektar (NKTR), Bristol-Myers (BMY) to end development program for bempegaldesleukin/Opdivo
Tickers: BMY, NKTR
Occurred on: Apr 14, 2022
Bristol Myers Squibb (BMY) Reports Opdivo (nivolumab) in Combination with CABOMETYX (cabozantinib) Survival Results in Patients with Advanced Renal Cell Carcinoma in Pivotal Phase 3 CheckMate -9ER Trial
Ticker: BMY
Occurred on: Sep 19, 2020
Celgene's (CELG) INREBIC (Fedratinib) gains FDA Approval as once-daily oral treatment in Myelofibrosis (bone marrow cancer)
Tickers: CELG, BMY
Occurred on: Aug 16, 2019
PRM-151 (pentraxin-2) Advances into Phase 2 Stage for Myelofibrosis - Study to Complete in 2017
Ticker: BMY
Occurred on: Jun 25, 2018
Phase 1/2 preliminary results of NKTR-214 (PEG-rhuIL-2) in combination with nivolumab in advanced solud tumors (PIVOT trial)
Tickers: NKTR, BMY
Occurred on: Jun 02, 2018
Bristol-Myers Squibb's (BMY) Phase 3 CheckMate of Opdivo Plus Low-Dose Yervoy in Lung Cancer Patients with High Tumor Mutational Burden Data Presented at AACR
Tickers: BMY, MRK
Occurred on: Apr 16, 2018
Phase 3 Data of Prostvac for Prostate Cancer Due Second Half of 2017
Tickers: 0DPB.L, BMY
Occurred on: Sep 14, 2017
FDA Grants Priority Review for Opdivo (nivolumab) in Previously Treated dMMR or MSI-H Metastatic Colorectal Cancer - PDUFA set for Aug. 2, 2017
Ticker: BMY
Occurred on: Aug 01, 2017
Data available 2H from Phase III study of Empliciti in first-line multiple myeloma
Tickers: BMY, ABBV
Occurred on: Jun 24, 2017
CHMP Recommends Approval of Bristol-Myers Squibb's (BMY) Opdivo as Single Agent for Squamous Cell Cancer of the Head and Neck After Platinum-Based Chemotherapy
Ticker: BMY
Occurred on: Mar 24, 2017
Bristol-Myers Squibb (BMY) and Pfizer (PFE) to Present New Analyses of Eliquis (apixaban) Clinical and Real-World Data at the American College of Cardiology 2017 Scientific Session taking place March 17-19
Tickers: BMY, PFE
Occurred on: Mar 17, 2017
OncoSec's (ONCS) ImmunoPulse Il-12 Granted Fast Track Status by FDA for Metastatic Melanoma Following Progression on Merck's (MRK) KEYTRUDA or Bristol-Myers Squibb's (BMY) Opdivo
Tickers: ONCS, BMY, MRK
Occurred on: Feb 27, 2017
FDA Approves Metformin Intellipharmaceutics' (IPCI) Generic Form of Bristol-Myers Squibb's (BMY) Type 2 Diabetes Med Glucophage XR
Tickers: IPCI, BMY
Occurred on: Feb 25, 2017
Bristol-Myers Squibb (BMY) Announces $2 Billion Accelerated Share Repurchase Program
Ticker: BMY
Occurred on: Feb 21, 2017
Bristol-Myers Squibb (BMY) Fails Phase 2 EkkiKIR Trial Evaluating Innate Pharma's (IPHYF) Lirilumab in Treatment of Acute Myeloid Leukemia (AML)
Tickers: BMY, IPHYF
Occurred on: Feb 06, 2017
PDUFA Date of March 2nd for BMY's Supplemental Biologics License Application (sBLA) for Opdivo in Patients With Locally Advanced Unresectable or Metastatic Urothelial Carcinoma After Platinum-Based Chemotherapy
Ticker: BMY
Occurred on: Feb 02, 2017
Japanese Authorities Mandate 50% Price Decrease for Bristol-Myers Squibb's (BMY) Cancer Medication Opdivo
Ticker: BMY
Occurred on: Nov 17, 2016
Bristol-Myers Squibb (BMY) Releases Phase 3 ONO-4538-12 Results Evaluating Opdivo in Patients with Unresectable Advanced or Recurrent Gastric Cancer Resistant to Standard Therapy
Ticker: BMY
Occurred on: Nov 10, 2016
New Bristol-Myers Squibb Research on Opdivo (nivolumab) Monotherapy and in Combination With Yervoy (ipilimumab) to be presented at SMR 2016 Congress Reinforces Immuno-Oncology Leadership and Scientific Expertise in Melanoma
Ticker: BMY
Occurred on: Nov 09, 2016
Bristol-Myers Squibb (BMY) Announces Positive Opinion from European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) on Opdivo for Classical Hodgkin Lymphoma
Ticker: BMY
Occurred on: Oct 14, 2016
Exelixis (EXEL) and Bristol-Myers Squibb (BMY) Present Phase 1 Data on CABOMETYX + Opdivo in Genitourinary Tumors at European Society for Medical Oncology 2016 Congress
Tickers: EXEL, BMY
Occurred on: Oct 11, 2016
FDA Concludes that Johnson & Johnson's (JNJ) Blood Thinner XARELTO is Safer Than Bristol-Myers Squibb's (BMY) Warfarin in Patients with Atrial Fibrillation
Tickers: BMY, JNJ, ALR
Occurred on: Oct 11, 2016
Exelixis (EXEL) and Bristol-Myers Squibb (BMY) to Present Phase 1b Data on Cobimetinib + Vemurafenib + Atezolizumab in Previously Untreated BRAF V600 Mutation-Positive Advanced Melanoma Monday October 10th
Tickers: EXEL, BMY
Occurred on: Oct 10, 2016
Bristol-Myers Squibb (BMY) Presents Data From Phase 3 CheckMate -026 Evaluating Opdivo Monotherapy Versus Chemotherapy in First-Line Treatment of Broad PD-L1 Positive Advanced Lung Cancer
Ticker: BMY
Occurred on: Oct 09, 2016
European Medicines Agency Accepts Bristol-Myers Squibb's (BMY) Marketing Application for New Use of Opdivo in Locally Advanced Unresectable or Metastatic Urothelial Carcinoma
Ticker: BMY
Occurred on: Sep 20, 2016
European Commission Approves Bristol-Myers Squibb’s ORENCIA (abatacept) for the Treatment of Highly Active and Progressive Disease in Adult Patients with Rheumatoid Arthritis Not Previously Treated with Methotrexate
Ticker: BMY
Occurred on: Sep 06, 2016
Bristol-Myers Squibb Announces Opdivo did not meet trial primary endpoint of progression-free survival in patients expressing PD-L1 = 5%
Ticker: BMY
Occurred on: Aug 05, 2016
CHMP Issues Positive Opinion for ORENCIA (abatacept) in the Treatment of Highly Active and Progressive Disease in Adult Patients with Rheumatoid Arthritis not Previously Treated with Methotrexate in the EU
Ticker: BMY
Occurred on: Jul 25, 2016
Bristol-Myers Squibb’s Response to ICER’s Draft Scoping Document “Treatment Options for Advanced Non-Small-Cell Lung Cancer”
Ticker: BMY
Occurred on: Jun 29, 2016
Bristol-Myers Squibb’s Opdivo (nivolumab) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Advanced Form of Bladder Cancer
Ticker: BMY
Occurred on: Jun 27, 2016
New Data on Bristol-Myers Squibb’s Opdivo (nivolumab) Indicate Benefit in Heavily Pre-Treated Classical Hodgkin Lymphoma Patients in Phase 2, Single-Arm Pivotal Trial
Ticker: BMY
Occurred on: Jun 10, 2016
EMA Decision on Regulatory Filings for Empliciti for Approval in Europe Due by April 1
Tickers: BMY, ABBV
Occurred on: May 11, 2016
European Commission Approves the First and Only Immuno-Oncology Combination, Bristol-Myers Squibb’s Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen, for Treatment of Advanced Melanoma
Ticker: BMY
Occurred on: May 11, 2016
Development of Varlilumab and Nivolumab (Opdivo) to Advance to Phase 2 Study - Open Enrollment to Begin Q2 of 2016
Tickers: CLDX, BMY
Occurred on: Apr 18, 2016
European Medicines Agency Validates Bristol-Myers Squibb’s Application for Opdivo(nivolumab) for the Treatment of Classical Hodgkin Lymphoma Patients
Ticker: BMY
Occurred on: Mar 30, 2016
CHMP Positive Opinions of Opdivo Recommend it Expand Existing Indication to Include Previously Treated Metastatic Non-squamous Non-small Cell Lung Cancer and Advanced Renal Cell Carcinoma
Ticker: BMY
Occurred on: Feb 26, 2016
Data Presented at APASL from First Completed Phase 3 Trial of All-oral Chronic Hepatitis C Regimen in Chinese Patient Population Shows Daclatasvir and Asunaprevir DUAL Therapy Demonstrated High Cure Rates Among HCV Genotype 1b Patients
Ticker: BMY
Occurred on: Feb 22, 2016
Bristol-Myers Squibb Completes Previously Announced Sale of its HIV R&D Portfolio to ViiV Healthcare
Ticker: BMY
Occurred on: Feb 22, 2016
US FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C
Ticker: BMY
Occurred on: Feb 05, 2016
Bristol-Myers Squibb (BMY) to Present Data from Several Studies on Hepatitis C Patients at Annual Meeting of The American Association for the Study of Liver Diseases 2015
Tickers: BMY, GILD, ABBV
Occurred on: Nov 17, 2015
European Medicines Agency Accepts Bristol-Myers Squibb's (BMY) Type II Variation Application Seeking Expanded Approval for the Treatment of Adults With Advanced Renal Cell Carcinoma
Tickers: BMY, NVS
Occurred on: Nov 05, 2015
Bristol-Myers Squibb (BMY) Acquires Cardioxyl Pharma for $2.1 Billion
Tickers: BMY, Cardioxyl Pharma
Occurred on: Nov 02, 2015
Bristol-Myers Squibb (BMY) Announces Complete Phase 2a Proof-of-Concept Study of BMS-955176 in Treatment of HIV-1
Tickers: BMY, GILD
Occurred on: Oct 23, 2015
Boehringer Ingelheim's Praxbind Approved by FDA for Use As an Emergency Reversing Agent in Patients Taking Pradaxa
Tickers: BOEHRINGER INGELHEIM, PTLA, BXLT, PFE, BMY
Occurred on: Oct 16, 2015

Strategic Initiatives (BMY)

Prothena (PRTA) Announces Bristol Myers Squibb (BMY) Opt-in of Anti-Tau PRX005 as the First Program from Global Neuroscience Research and Development Collaboration
Tickers: PRTA, BMY
Announcement Date: Jun 24, 2021
Schrödinger (SDGR) Announces a Multi-Target Drug Discovery, Development, and Commercialization Collaboration with Bristol Myers Squibb (BMY)
Tickers: SDGR, BMY
Announcement Date: Nov 23, 2020
Bristol-Myers Squibb (BMY) Enters Collaboration Agreement with Calithera Biosciences (CALA) to Evaluating Opdivo + CB-839 in Clear Cell Renal Cell Carcinoma
Tickers: CALA, BMY
Announcement Date: Dec 21, 2016
Bristol-Myers Squibb (BMY) Reaches Exclusive Worldwide Agreement with PsiOxus Therapeutics to Develop an "Armed" Oncolytic Virus NG-348 to Treat Solid Tumors
Tickers: BMY, PsiOxus Therapeutics
Announcement Date: Dec 20, 2016
Rosetta Genomics (ROSG) Enters Research Collaboration to Develop Test Predicting Response to Bristol-Myers Squibb's (BMY) Opdivo
Tickers: ROSG, BMY
Announcement Date: Nov 21, 2016
Roche (RHHBY) and Bristol-Myers Squibb (BMY) Announce Decrease in Cancer Drug Prices for Access to Britain's National Health Service (NHS)
Tickers: BMY, RHHBY
Announcement Date: Nov 17, 2016
Bristol-Myers Squibb (BMY) Announces Collaboration Agreement with Enterome to Develop Microbiome-Derived Biomarkers for Cancer
Tickers: BMY, Enterome
Announcement Date: Nov 16, 2016
Bristol-Myers Squibb (BMY) Signs Exclusive Worldwide License Agreement with Nitto Denko (NDEKY) for siRNA Therapy in Advanced Non-Alcoholic Steatohepatitis (NASH) and Cirrhosis
Tickers: BMY, NDEKY
Announcement Date: Nov 10, 2016
Bristol-Myers Squibb (BMY) and Infinity Pharma (INFI) Announce Collaboration Agreement to Study Opdivo and IPI-549 in Patients with Advanced Solid Tumors
Tickers: INFI, BMY
Announcement Date: Nov 09, 2016
Lexicon Pharma (LXRX) Acquires Exclusive Research Rights from Bristol-Myers Squibb (BMY) for Neuropathic Pain Candidate LX9211
Tickers: BMY, LXRX
Announcement Date: Nov 07, 2016
Bristol-Myers Squibb (BMY) Announces Evolution Plan to Increase Investment in Research and Development
Ticker: BMY
Announcement Date: Oct 27, 2016
Janssen Announces Clinical Collaboration with Bristol-Myers Squibb to Evaluate Immuno-oncology Combination in Lung Cancer
Tickers: JNJ, BMY
Announcement Date: Jul 26, 2016
AbbVie and Bristol-Myers Squibb Announce Oncology Clinical Collaboration to Evaluate the Combination of Rova-T plus Opdivo and Opdivo + Yervoy Regimen
Tickers: BMY, ABBV
Announcement Date: Jul 25, 2016
Bristol-Myers Squibb Acquires Cormorant Pharmaceuticals
Tickers: BMY, Cormorant Pharmaceuticals
Announcement Date: Jul 05, 2016
Bristol-Myers Squibb and PsiOxus Therapeutics Announce Immuno-Oncology Clinical Collaboration to Evaluate the Combination of Opdivo and Enadenotucirev
Tickers: BMY, PsiOxus Therapeutics
Announcement Date: Jun 30, 2016
Bristol-Myers Squibb to Acquire Padlock Therapeutics, Inc.; Bristol-Myers Squibb and Padlock anticipate the transaction will close during the second quarter of 2016.
Tickers: BMY, Padlock Therapeutics
Announcement Date: Mar 23, 2016
Bristol-Myers Squibb and Pfizer Sign Collaboration with Portola Pharmaceuticals to Develop and Commercialize Investigational Andexanet Alfa in Japan
Tickers: BMY, PFE, PTLA
Announcement Date: Feb 02, 2016
Oncodesign Biotechnology and Bristol-Myers Squibb enter into Strategic Drug Discovery Collaboration
Tickers: ALONC.PA, BMY
Announcement Date: Jan 05, 2016